Bright Light Therapy for Post-COVID-19 Fatigue

This is a randomized placebo-controlled trial to examine the efficacy of two-week bright light therapy for patients with post-COVID-19 fatigue.

Inclusion Criteria:Age 18 or aboveCapable to give informed consentCOVID-19 infection confirmed by PCR test or a Rapid Antigen Test (RAT) with onset of at least three monthsReports new onset or exacerbation of fatigue after onset of COVID-19 and lasted for over two monthsScoring 7 or above for the item "worst level of fatigue during the last 24 hours" in the Brief Fatigue InventoryExclusion Criteria:A current or past history of bipolar disorder, schizophrenia, neurodevelopmental disorder, organic mental disorder; intellectual disabilities or substance use disorder.Presence of contraindications to bright light therapy: for example, history of light induced migraine/ epilepsy; current use of photosensitizing medications; presence of eye disease: e.g. retinal blindness, severe cataract, glaucoma.Significant medical condition/ hearing impairment/ speech deficit leading to incapability of completing clinical interview.Regular shift-workersTrans-meridian flight in the past 3 months and during the studyCurrently receiving any structured psychotherapySelf-reported untreated sleep disorders (e.g. severe insomnia, obstructive sleep apnea, restless leg syndrome), psychiatric illness (e.g. depression), or medical conditions associated with fatigue (e.g. anemia, heart failure, autoimmune disorders)Enrolment in another clinical trial of an investigational medicinal product or device.